Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews · Epilepsy

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 2 · 25%Low 0 · 0%Moderate 0 · 0%High 4 · 50%

VGB vs CBZ monotherapy

Adverse events Visual field defects · people with epilepsy

It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).

1 finding from 1 review

Vigabatrin versus carbamazepine monotherapy for epilepsy 2015 · Cochrane Headline outcomes only
RR 5.37 [0.27, 106.88]
1 study · 54 participants
Very low

Intervention not reported

Adverse events · adults and children with focal seizures

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 520 participants
High

Intervention not reported

Adverse events · adults and children with focal seizures

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 2203 participants
High

Intervention not reported

Adverse events · adults and children with generalised tonic‐clonic seizures with or without other seizure types

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 117 participants
High

Oxcarbazepine vs phenytoin

Time to treatment failure due to adverse events All participants Range of · people with newly diagnosed epilepsy

Summary of findings: oxcarbazepine leads to lower time to treatment failure due to adverse events All participants… compared with phenytoin (primary outcomes) (high certainty).

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.22 [0.1, 0.51]
2 studies · 480 participants
High

Clonazepam vs carbamazepine

Adverse events during treatment period · people with newly diagnosed epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Clonazepam monotherapy for treating people with newly diagnosed epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clonazepam vs ethosuximide

Adverse events during treatment period · people with newly diagnosed epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Clonazepam monotherapy for treating people with newly diagnosed epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clonazepam vs carbamazepine

Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) · people with newly diagnosed epilepsy

It is very uncertain whether clonazepam changes proportion of participants with treatment‐emergent adverse events… compared with carbamazepine (very low certainty).

1 finding from 1 review

Clonazepam monotherapy for treating people with newly diagnosed epilepsy 2022 · Cochrane Headline outcomes only
RR 2.61 [0.8, 8.52]
Studies not reported
Very low